A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

NCT07438106 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Pancreatic Cancer With KRAS G12D Mutation

Interventions

DRUG: HRS-4642 Injection

Sponsor

The First Affiliated Hospital with Nanjing Medical University